1st Quarter 2019

Financial Highlights

Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016. 

First Quarter (2019-01-01 – 2019-03-31)
  • Net revenues were TDKK 0 (0)
  • EBIT was TDKK -1,463 (-3,111)
  • Earnings per share was DKK –0.06 (-0.38)
  • Cash and bank: TDKK 13,346 (14,491 as of 2018.12.31)
  • Solidity: 94%

Group earnings per share: period result divided by 23 157 178 shares (on 2019-03-31).

Solidity: equity divided by total assets.  

Business highlights in Q1 2019

  • None

Significant events after this reporting period­

  • None

Update on the ongoing Phase 1 trial for IPED2015

The Phase 1 trial is progressing well, and  we expect to complete the trial shortly with supportive data for  continuing with the Phase 2a trial. We still expect to report phase 1 data during H1:2019. If successful we plan to immediately progress the compound into a phase 2a clinical proof of concept trial, with headline data available mid-2019.

Comments from the CEO

”We are very pleased with the progress of the Phase 1 trial and satisfied with the general conductance of the trial by MAC Clinical research, including the continuing recruitment of healthy subjects. We are looking forward to completing the Phase I study and are now preparing for the upcoming Phase 2a trial. We appreciate the support from existing and new shareholders and look forward to reporting data from our Proof-of- Concept study around mid-year”.

For more information, please contact

Claus Olesen, CEO, Initiator Pharma, Mobile: +45-61 26 00 35, E-mail: ceo@initiatorpharma.com 

Torgeir Vaage, CFO, Initiator Pharma, Mobile: +47-924 05 235, E-mail: tv@initiatorpharma.com 

About Initiator Pharma 

Initiator Pharma A/S is a Danish biotechnology company focusing on the development of innovative drugs, targeting key unmet medical needs within the central and peripheral nervous system. Our research is focusing on monoamine reuptake inhibitors, molecules that are affecting the synaptic concentrations of neurotransmitters such as dopamine, serotonin and noradrenaline. Our lead drug candidate, IPED2015 is targeting the medical condition Erectile Dysfunction (ED), and specifically patients with ED that are non-responsive to drugs within the PDE5i class, including the approved drugs ViagraÓ, CialisÓand LevitraÓ.

Initiator Pharma is based in Aarhus, Denmark.  Initiator Pharma is listed on Spotlight Stockmarket and has about 3.500 shareholders. Read more at www.initiatorpharma.com.

Subscribe

Documents & Links